# Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus

> **NCT00091819** · PHASE3 · COMPLETED · sponsor: **Cumberland Pharmaceuticals** · enrollment: 862 (actual)

## Conditions studied

- Staphylococcal Skin Infection

## Interventions

- **DRUG:** Telavancin
- **DRUG:** Vancomycin

## Key facts

- **NCT ID:** NCT00091819
- **Lead sponsor:** Cumberland Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01
- **Primary completion:** 2006-06
- **Final completion:** 2006-06
- **Target enrollment:** 862 (ACTUAL)
- **Last updated:** 2019-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00091819

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00091819, "Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00091819. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*